Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07428538 | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | PHASE3 | RECRUITING | 350 | — | — | Jan 29, 2026 | Feb 1, 2028 | May 7, 2026 | 48 | United States |
| Arm | Type | Description |
|---|---|---|
| Larsucosterol 30 mg | EXPERIMENTAL | Participants will receive Larsucosterol 30 milligrams (mg) intravenous infusion on Day 1. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive intravenous infusion of placebo matched to Larsucosterol on Day 1. |
| Name | Type | Description |
|---|---|---|
| Larsucosterol | DRUG | Larsucosterol intravenous infusion. |
| Placebo | DRUG | Matching-placebo (sterile water for injection) intravenous infusion. |
Inclusion Criteria- A participant will be eligible for inclusion in this study if he/she meets all the following criteria: 1. Able to provide written informed consent (either from participant or participant's legally acceptable representative). 2. Onset of jaundice within 8 weeks before hospital a...